Abstract: A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Abstract: The present technology provides a method for the effective participation of tissue, for example, amniotic, chorionic, umbilical cord, or a combination thereof to create a flowable suspension for therapeutic purposes. In contrast to other technologies, the present technology does not require cryogenic milling or pre-freezing to harden the tissue for effective particulation and is further capable of preserving the viability of endogenous cell types in contrast to previous methodologies.

Abstract: Diagnostic tests and methods to assess the characteristics of a patient's native stem cell populations. A reference cell source may be selected for testing, to determine the relative health and potency of the cell population derived from that cell source based on standardized testing protocols, and to use the results to evaluate the systemic stem cell health status of the patient across the many different cell populations residing in different tissues in the body.

Abstract: The present invention relates to the isolation, propagation and use of prenatal stem cells. The cells are CD105 negative. In certain embodiments the cells are also SSEA-4 positive or negative, and c-kit negative. The cells may be isolated from a prenatal sample, for instance third trimester amniotic fluid or placental membrane. The cells may be combined with a biologically compatible solution or a biologically compatible matrix and utilized to treat a human subject. The invention also contemplated enriched populations of prenatal stem cells. The enriched cell population may be propagated in the appropriate culture medium and the resulting progeny cells utilized therapeutic applications.

Abstract: A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Abstract: A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Abstract: A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Abstract: A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Abstract: The present invention relates to the isolation, propagation and use of prenatal stem cells. The cells are CD105 negative. In certain embodiments the cells are also SSEA-4 positive or negative, and c-kit negative. The cells may be isolated from a prenatal sample, for instance third trimester amniotic fluid or placental membrane. The cells may be combined with a biologically compatible solution or a biologically compatible matrix and utilized to treat a human subject. The invention also contemplated enriched populations of prenatal stem cells. The enriched cell population may be propagated in the appropriate culture medium and the resulting progeny cells utilized therapeutic applications.

Abstract: Preparations derived from placental materials and methods of making and using same, the preparations including a first preparation composed of placental membranes digested in collagenase, a second preparation composed of multipotent cells derived from the collagenase digested placental membranes and that are grown in adherent culture beyond confluence and a third preparation composed of ground placental membranes re-suspended in a fluid containing hyaluronic acid. The preparations can be used for regenerating damaged or defective tissue including connective tissue, nerve tissue, muscle tissue, skin tissue, cartilage tissue and bone tissue. The preparations can also be used as dermal fillers in cosmetic and plastic surgery applications.